Appert-Collin A, Hubert P, Cremel G, Bennasroune A. Role of ErbB receptors in cancer cell migration and invasion. Front Pharm. 2015;6:283.
Google ScholarÂ
Arteaga CL, Engelman JA. ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics. Cancer Cell. 2014;25:282–303.
Google ScholarÂ
Jacobi N, Seeboeck R, Hofmann E, Eger A. ErbB Family Signalling: A Paradigm for Oncogene Addiction and Personalized Oncology. Cancers. 2017;9:1–24.
Swain SM, Shastry M, Hamilton E. Targeting HER2-positive breast cancer: advances and future directions. Nat Rev Drug Discov. 2023;22:101–26.
Google ScholarÂ
Maennling AE, Tur MK, Niebert M, Klockenbring T, Zeppernick F, Gattenlohner S, et al. Molecular targeting therapy against EGFR family in breast cancer: progress and future potentials. Cancers. 2019;11:1–19.
Gandullo-Sanchez L, Ocana A, Pandiella A. HER3 in cancer: from the bench to the bedside. J Exp Clin Cancer Res. 2022;41:310.
Google ScholarÂ
Howlader N, Altekruse SF, Li CI, Chen VW, Clarke CA, Ries LA, et al. US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. J Natl Cancer Inst. 2014;106:1–8.
Chaput G, Sumar N. Endocrine therapies for breast and prostate cancers: Essentials for primary care. Can Fam Physician. 2022;68:271–6.
Google ScholarÂ
Johnston SR. New strategies in estrogen receptor-positive breast cancer. Clin Cancer Res. 2010;16:1979–87.
Google ScholarÂ
Haque MM, Desai KV. Pathways to endocrine therapy resistance in breast cancer. Front Endocrinol (Lausanne). 2019;10:573.
Google ScholarÂ
Hashimoto Y, Koyama K, Kamai Y, Hirotani K, Ogitani Y, Zembutsu A, et al. A Novel HER3-Targeting Antibody-Drug Conjugate, U3-1402, Exhibits Potent Therapeutic Efficacy through the Delivery of Cytotoxic Payload by Efficient Internalization. Clin Cancer Res. 2019;25:7151–61.
Google ScholarÂ
Krop IE, Masuda N, Mukohara T, Takahashi S, Nakayama T, Inoue K, et al. Patritumab Deruxtecan (HER3-DXd), a Human Epidermal Growth Factor Receptor 3-Directed Antibody-Drug Conjugate, in Patients With Previously Treated Human Epidermal Growth Factor Receptor 3-Expressing Metastatic Breast Cancer: A Multicenter, Phase I/II Trial. J Clin Oncol. 2023;41:5550–60.
Google ScholarÂ
Hamilton EP, Dosunmu O, Shastry M, Finney L, Sellami DB, Sternberg DW, et al. A Phase 2 study of HER3-DXd in patients (pts) with metastatic breast cancer (MBC). J Clin Oncol. 2023;41:1004.
Pistilli B, Mosele F, Corcos N, Pierotti L, Pradat Y, Le Bescond L, et al. A Phase 2 Study of Patritumab Deruxtecan (HER3-DXd) in patients with advanced breast cancer: An exploratory biomarker analysis. ESMO Open. 2023;8.
Preusser M, Garde J, Gion M, Ruiz M, Garcia-Mosquera JJ, Greil R, et al. Patritumab deruxtecan (HER3-DXd) in active brain metastases (BM) from metastatic breast (mBC) and non–small cell lung cancers (aNSCLC), and leptomeningeal disease (LMD) from advanced solid tumors: Results from the TUXEDO-3 Phase II trial. J Clin Oncol. 2025;43:2005.
Marechal A, Zou L. DNA damage sensing by the ATM and ATR kinases. Cold Spring Harb Perspect Biol. 2013;5:1–17.
Biswas H, Makinwa Y, Zou Y. Novel Cellular Functions of ATR for Therapeutic Targeting: Embryogenesis to Tumorigenesis. Int J Mol Sci. 2023;24:1–20.
Brown EJ, Baltimore D. ATR disruption leads to chromosomal fragmentation and early embryonic lethality. Genes Dev. 2000;14:397–402.
Google ScholarÂ
Chandrashekar DS, Bashel B, Balasubramanya SAH, Creighton CJ, Ponce-Rodriguez I, Chakravarthi B, et al. UALCAN: a portal for facilitating tumor subgroup gene expression and survival analyses. Neoplasia. 2017;19:649–58.
Google ScholarÂ
Lanczky A, Gyorffy B. Web-Based Survival Analysis Tool Tailored for Medical Research (KMplot): Development and Implementation. J Med Internet Res. 2021;23:e27633.
Google ScholarÂ
Xie X, Lee J, Fuson JA, Liu H, Iwase T, Yun K, et al. Identification of kinase targets for enhancing the antitumor activity of eribulin in triple-negative breast cell lines. Biomedicines. 2023;11:1–23.
Xie X, Manai M, Rampa DR, Fuson JA, Nakasone ES, Pearson T, et al. Targeting CDK7 enhances the antitumor efficacy of enzalutamide in androgen receptor-positive triple-negative breast cancer by inhibiting c-MYC-mediated Tumorigenesis. Mol Cancer Ther. 2025;24:870–83.
Google ScholarÂ
Bartholomeusz C, Gonzalez-Angulo AM, Kazansky A, Krishnamurthy S, Liu P, Yuan LX, et al. PEA-15 inhibits tumorigenesis in an MDA-MB-468 triple-negative breast cancer xenograft model through increased cytoplasmic localization of activated extracellular signal-regulated kinase. Clin Cancer Res. 2010;16:1802–11.
Google ScholarÂ
Xie X, Kaoud TS, Edupuganti R, Zhang T, Kogawa T, Zhao Y, et al. c-Jun N-terminal kinase promotes stem cell phenotype in triple-negative breast cancer through upregulation of Notch1 via activation of c-Jun. Oncogene. 2017;36:2599–608.
Google ScholarÂ
Belachew EB, Sewasew DT. Molecular mechanisms of endocrine resistance in estrogen-positive breast cancer. Front Endocrinol. 2021;12:599586.
Google ScholarÂ
Jordan VC, O’Malley BW. Selective estrogen-receptor modulators and antihormonal resistance in breast cancer. J Clin Oncol. 2007;25:5815–24.
Google ScholarÂ
Zhao H, Huang X, Halicka HD, Darzynkiewicz Z. Detection of Histone H2AX Phosphorylation on Ser-139 as an Indicator of DNA Damage. Curr Protoc Cytom. 2019;89:e55.
Google ScholarÂ
Lee YC, Zhou Q, Chen J, Yuan J. RPA-binding protein ETAA1 Is an ATR activator involved in DNA replication stress response. Curr Biol. 2016;26:3257–68.
Google ScholarÂ
Anurag M, Punturi N, Hoog J, Bainbridge MN, Ellis MJ, Haricharan S. Comprehensive profiling of dna repair defects in breast cancer identifies a novel class of endocrine therapy resistance drivers. Clin Cancer Res. 2018;24:4887–99.
Google ScholarÂ
Traphagen NA, Schwartz GN, Tau S, Roberts AM, Jiang A, Hosford SR, et al. Estrogen therapy induces receptor-dependent DNA damage enhanced by PARP inhibition in ER+ breast cancer. Clin Cancer Res. 2023;29:3717–28.
Google ScholarÂ
Thein KZ, Thawani R, Kummar S. Combining Poly (ADP-Ribose) Polymerase (PARP) inhibitors with chemotherapeutic agents: promise and challenges. Cancer Treat Res. 2023;186:143–70.
Google ScholarÂ
Hunia J, Gawalski K, Szredzka A, Suskiewicz MJ, Nowis D. The potential of PARP inhibitors in targeted cancer therapy and immunotherapy. Front Mol Biosci. 2022;9:1073797.
Google ScholarÂ
Li J, Jia Z, Dong L, Cao H, Huang Y, Xu H, et al. DNA damage response in breast cancer and its significant role in guiding novel precise therapies. Biomark Res. 2024;12:111.
Google ScholarÂ
Kim H, Xu H, George E, Hallberg D, Kumar S, Jagannathan V, et al. Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models. Nat Commun. 2020;11:3726.
Google ScholarÂ
Abelman RO, Spring L, Niemierko A, Abraham E, McNeice M, Goff J, et al. Sequential combination of sacituzumab govitecan and talazoparib in metastatic triple negative breast cancer (mTNBC): Results from a Phase II study. J Clin Oncol. 2024;42:1102.
A Matulonis; Geoffrey I. Shapiro; Panagiotis A. Konstantinopoulos EKLAEWHGC-OCAPNXS-CCMPHSMHU. A Phase 1 study of DS-8201a in combination with olaparib in HER2-expressing malignancies (CTEP #10355): Results of module 1 dose escalation. Mol Cancer Ther. 2023;22:B041–B041.
Li Y, Li L, Fu H, Yao Q, Wang L, Lou L. Combined inhibition of PARP and ATR synergistically potentiates the antitumor activity of HER2-targeting antibody-drug conjugate in HER2-positive cancers. Am J Cancer Res. 2023;13:161–75.
Google ScholarÂ
Lee J, Kida K, Koh J, Liu H, Manyam GC, Gi YJ, et al. The DNA repair pathway as a therapeutic target to synergize with trastuzumab deruxtecan in HER2-targeted antibody-drug conjugate-resistant HER2-overexpressing breast cancer. J Exp Clin Cancer Res. 2024;43:236.
Google ScholarÂ
Martorana F, Da Silva LA, Sessa C, Colombo I. Everything comes with a price: the toxicity profile of DNA-damage response targeting agents. Cancers. 2022;14:1–22.
Ngoi NYL, Pham MM, Tan DSP, Yap TA. Targeting the replication stress response through synthetic lethal strategies in cancer medicine. Trends Cancer. 2021;7:930–57.
Google ScholarÂ
Yap TA, Tan DSP, Terbuch A, Caldwell R, Guo C, Goh BC, et al. First-in-Human Trial of the Oral Ataxia Telangiectasia and RAD3-Related (ATR) Inhibitor BAY 1895344 in patients with advanced solid tumors. Cancer Discov. 2021;11:80–91.
Google ScholarÂ
Li K, Sun X, Liu S, Liu Y, Feng X, Zhang G. A medicinal chemistry perspective on ATR: Current status and future directions. Eur J Med Chem. 2025;296:117834.
Google ScholarÂ
Heumann TR, Stockton S, Cecchini M, Aljumaily R, Shyr C, Whisenant J, et al. A Phase I study of ATR inhibitor BAY1895344 (elimusertib) plus topotecan (ETCTN 10402): Results of dose escalation. J Clin Oncol. 2024;42:3076.
Heumann TR, Stockton S, Cecchini M, Aljumaily R, Shyr C, Whisenant J, et al. A Phase I study of irinotecan combined with BAY1895344 (ATR inhibitor) in advanced solid tumors: Results of ETCTN 10402 dose escalation. J Clin Oncol. 2024;42:3077.
Mowery YM, Niedzwiecki D, Choe JH, Kirsch DG, Brizel DM. Phase I trial of the ATR inhibitor BAY 1895344 combined with stereotactic body radiation therapy and pembrolizumab for recurrent head and neck squamous cell carcinoma. J Clin Oncol. 2022;40.
Janne PA, Baik C, Su WC, Johnson ML, Hayashi H, Nishio M, et al. Efficacy and safety of Patritumab Deruxtecan (HER3-DXd) in EGFR inhibitor-resistant, EGFR-mutated non-small cell lung cancer. Cancer Discov. 2022;12:74–89.
Google ScholarÂ
Ding K, Li W, Zou Z, Zou X, Wang C. CCNB1 is a prognostic biomarker for ER+ breast cancer. Med Hypotheses. 2014;83:359–64.
Google ScholarÂ
Gao T, Han Y, Yu L, Ao S, Li Z, Ji J. CCNA2 is a prognostic biomarker for ER+ breast cancer and tamoxifen resistance. PLoS One. 2014;9:e91771.
Google ScholarÂ
Liu NQ, Cao WH, Wang X, Chen J, Nie J. Cyclin genes as potential novel prognostic biomarkers and therapeutic targets in breast cancer. Oncol Lett. 2022;24:374.
Google ScholarÂ
Al-Ansari MM, Al-Saif M, Arafah M, Eldali AM, Tulbah A, Al-Tweigeri T, et al. Clinical and functional significance of tumor/stromal ATR expression in breast cancer patients. Breast Cancer Res. 2020;22:49.
Google ScholarÂ
Alsubhi N, Middleton F, Abdel-Fatah TM, Stephens P, Doherty R, Arora A, et al. Chk1 phosphorylated at serine345 is a predictor of early local recurrence and radio-resistance in breast cancer. Mol Oncol. 2016;10:213–23.
Google ScholarÂ
Forma E, Krzeslak A, Bernaciak M, Romanowicz-Makowska H, Brys M. Expression of TopBP1 in hereditary breast cancer. Mol Biol Rep. 2012;39:7795–804.
Google ScholarÂ
Cybulski C, Zamani N, Kluzniak W, Milano L, Wokolorczyk D, Stempa K, et al. Variants in ATRIP are associated with breast cancer susceptibility in the Polish population and UK Biobank. Am J Hum Genet. 2023;110:648–62.
Google ScholarÂ
Lashen A, Alqahtani S, Shoqafi A, Algethami M, Jeyapalan JN, Mongan NP, et al. Clinicopathological Significance of Cyclin-Dependent Kinase 2 (CDK2) in Ductal Carcinoma In Situ and Early-Stage Invasive Breast Cancers. Int J Mol Sci. 2024;25:1–15.
Satriyo PB, Su CM, Ong JR, Huang WC, Fong IH, Lin CC, et al. 4-Acetylantroquinonol B induced DNA damage response signaling and apoptosis via suppressing CDK2/CDK4 expression in triple negative breast cancer cells. Toxicol Appl Pharm. 2021;422:115493.
Google ScholarÂ
Yang Y, Zhang GJ, Zhang YD. Expression and prognostic analysis of CDKs in breast cancer. Ann Breast Cancer Res. 2025;9:1031.
Katsuta E, Sawant Dessai A, Ebos JM, Yan L, Ouchi T, Takabe K. H2AX mRNA expression reflects DNA repair, cell proliferation, metastasis, and worse survival in breast cancer. Am J Cancer Res. 2022;12:793–804.
Google ScholarÂ
